Close Menu

NEW YORK (GenomeWeb) — Bristol-Myers Squibb and H3 Biomedicine said today that they have partnered to investigate the therapeutic potential of H3's RNA splicing technology.

H3 — a Cambridge, Massachusetts-based subsidiary of Japanese drugmaker Eisai — is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jun
02
Sponsored by
NanoString

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.